The Division of Rheumatology strives to understand more about scleroderma and systemic sclerosis through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
|Scleroderma Lung Study III (SLS III)
|The purpose of the study is
to research a new treatment
for Scleroderma related lung
|To qualify for study participation, you must be:
- Over 18 years old
- Diagnosed with Scleroderma (SSc) with in the last 7 years
- Diagnosed with Interstitial Lung Disease (ILD)
- No smoking in the last 6 months
- Not pregnant or breastfeeding
|PI: Aryeh Fischer, MD|
Mallary Crow Adams
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.